NJAAIS 2023 Annual Teaching Day

Long Branch, NJ US
September 29, 2023

The New Jersey Allergy, Asthma & Immunology Society's Annual Teaching Day is an event for allergy professionals from the New Jersey area to get together for education, exchange of knowledge and networking through formal symposiums and discussions. The symposium features invited speakers who are leaders and experts in the fields of allergy, asthma, and immunology. It aims to update attendees the current knowledge, guidelines and discoveries in various topics, and encourage implantation measurements for advancement in clinical practice and patient advocacy. Topics this year include eczema treatment, OIT for food allergy, PIDD updates, hidden food allergies, ENT issues for allergists and updates on asthma treatment.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and The New Jersey Allergy, Asthma & Immunology Society (NJAAIS).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Physicians
Allied Health Practitioners

Learning Objectives

At the conclusion of this Activity learners should be able to…

1. Interpret the clinical data of different biologics.
2. Compare the efficacy of different biologics in specific clinical scenarios.
3. Develop strategies to incorporate correct biologics with the care of appropriate clinical scenarios.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
09/29/2023
Course expires: 
12/31/2024
Event starts: 
09/29/2023 - 8:30am CDT
Event ends: 
09/29/2023 - 5:30pm CDT
Add to calendar: 
Rating: 
0

2023 New Jersey Allergy, Asthma & Immunology Teaching Day

September 29, 2023

6:45-8:30 am Registration & Continental Breakfast – Sponsored by NJAAIS

8:30-9:30 am Eczema Treatment Updates and Itch without Rash, Marc Serota, MD

9:30-10:30 am Oral Immunotherapy for Food Allergy Updates, Richard Wasserman, MD

10:30-11:00 am Mid-morning Break/Exhibit Hall

11:00 am -12:00 pm Clinical Applications and Updates for Primary Immunodeficiency, Antoine Azar, MD

12:00-1:30 pm Lunch – Sponsored by NJAAIS

1:30-2:30 pm Where Should We Look for Hidden Food Allergies, Sami Bahna, MD

2:30-3:30 pm ENT issues for Allergists, Joseph Han, MD

3:30-4:00 pm Afternoon Break/Exhibit Hall

4:00-5:00 pm Updates on Asthma Treatments and Biologics, Yamini Virkud, MD

5:00-5:30 pm NJAAIS Final Remarks & Annual Member Meeting

The Ocean Place
One Ocean Boulevard
Long Branch, NJ 07740
United States

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All relevant financial relationships with ineligible companies have been mitigated.

John Kim, MD, Planner
Speaker: Sanofi Regeron, Genzyme

Antoine Azar, Speaker
Speaker: Grifols
Researcher: X4, Grifols, Argent
Consultant: Takeda, Jassen, Pfizer, ArgenX

Joseph Han, MD, Speaker
Researcher: Sanofi Regeneron, GlaxoSmithKline, AstraZeneca, Genentech Novartis 

Marc Serota, MD, Speaker
Speaker: Sanofi Regeneron, Dermavant, Arcutis, Incyte, BMS 

Richard Wasserman, MD, speaker
Speaker: GSK, Sanofi, Grifols, Takeda
Advisor: Sanofi
Consultant: Aimmune, Grifols, Takeda
Researcher: Cour Pharmaceutical, Takeda


The following have no relevant financial relationships with ineligible companies to disclose:
 
Erin Toller-Artis, DO, Planner

Lisa Barisciano, MD, Planner

Lin Li, MD, Planner

Naba Sharif, MD, Planner

Sami Bahna, MD, Speaker

Yamini Virkud, MD, Speaker
 

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or create an account to take this course.